Yale University

Lack of reduction in buprenorphine injection after introduction of co-formulated buprenorphine/naloxone to the Malaysian market.

TitleLack of reduction in buprenorphine injection after introduction of co-formulated buprenorphine/naloxone to the Malaysian market.
Publication TypeJournal Article
Year of Publication2009
AuthorsBruce, Douglas R., Sumathi Govindasamy, Laurie Sylla, Adeeba Kamarulzaman, and Frederick L. Altice
JournalThe American journal of drug and alcohol abuse
Volume35
Issue2
Pagination68-72
Date Published2009
ISSN1097-9891
KeywordsAdult, Buprenorphine, Drug Combinations, Humans, Logistic Models, Malaysia, Male, Middle Aged, Naloxone, Narcotic Antagonists, Needle Sharing, Opioid-Related Disorders, Risk-Taking, Substance Abuse, Intravenous, Substance Withdrawal Syndrome, Young Adult
AbstractDiversion of buprenorphine (BPN) has been described in settings where it is legally prescribed and has resulted in increasing concern. To address this concern, co-formulation of buprenorphine/naloxone (BPN/NLX) replaced buprenorphine alone in Malaysia in December 2006.
DOI10.1080/00952990802585406
Alternate JournalAm J Drug Alcohol Abuse

External Links